KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Profit After Tax: 2020-2025

Historic Profit After Tax for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Profit After Tax fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Profit After Tax stood at -$162.3 million, which was up 5.61% from -$171.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Profit After Tax high stood at -$30.7 million for Q1 2021, and its period low was -$202.5 million during Q1 2025.
  • In the last 3 years, Recursion Pharmaceuticals' Profit After Tax had a median value of -$95.8 million in 2024 and averaged -$120.8 million.
  • In the last 5 years, Recursion Pharmaceuticals' Profit After Tax plummeted by 152.01% in 2021 and then grew by 11.46% in 2022.
  • Recursion Pharmaceuticals' Profit After Tax (Quarterly) stood at -$64.9 million in 2021, then grew by 11.46% to -$57.5 million in 2022, then slumped by 61.75% to -$93.0 million in 2023, then slumped by 92.38% to -$178.9 million in 2024, then plummeted by 69.29% to -$162.3 million in 2025.
  • Its Profit After Tax was -$162.3 million in Q3 2025, compared to -$171.9 million in Q2 2025 and -$202.5 million in Q1 2025.